Technology
A localized, sustained-release platform.
Bypassing systemic toxicity with intra-peritoneal delivery. Disease modification, locally and continuously.
Simple Administration
Intra-peritoneal administration using a standard procedure, just once every three months.
Targeted Encapsulation
The active agent is loaded into the novel drug delivery system, sitting locally on the lesions.
Precision Release
Slowly releases continuous low doses over three months, inhibiting estrogen supply directly at the root cause.
The Systemic Barrier
Local peritoneal retention prevents systemic absorption into the bloodstream, completely bypassing menopause-like side effects.
Why it matters
Inhibiting estrogen supply directly at the lesions.
Efficacy
MS-LTZ targets the estrogen-producing enzyme directly at the lesion site, cutting off local estrogen supply for direct disease modification at the source.
Safety
Peritoneal retention confines drug delivery locally, preventing systemic absorption and eliminating menopausal side effects entirely.
Patient-centered
A single administration delivers three months of continuous low-dose release. No daily pills, no hormonal rollercoaster, no clinic burden.